Paclitaxel monotherapy (Kaposi sarcoma, post-anthracycline)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-PACLITAXEL |
|---|
| ID | REG-PACLITAXEL-KAPOSI |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-07-11 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | None declared |
Notes
New Regimen entity reusing the existing DRUG-PACLITAXEL Drug entity. DRUG-PACLITAXEL already documents "Kaposi sarcoma (AIDS-related, 2L)" as an FDA-approved indication (regulatory_status.fda.indications_brief -- pre-existing fact, transcribed not invented, verified by direct read of drugs/paclitaxel.yaml during independent review) but its typical_dosing field does not carry a Kaposi-specific mg/m²/schedule figure, and no KB-verifiable primary source for that figure was available at authoring time. Per CHARTER §8.3 ("must NEVER invent a dose ..."), the `dose`/`schedule` component fields are deliberately left as an explicit flagged gap rather than a fabricated number -- this is an intentional, disclosed omission, not an authoring oversight. The mandatory Cremophor-EL hypersensitivity premedication IS transcribed from the existing DRUG-PACLITAXEL entity because that fact is dose-independent and already verified in the KB. INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 for the dose-adjustment items and the file's top-level sources. That source documents only basal-cell/squamous- cell skin cancer (confirmed by direct inspection of its own KB reco...
Used By
Disease
DIS-KAPOSI- Kaposi sarcoma
Indication
IND-KAPOSI-2L-VISCERAL-PACLITAXEL- IND-KAPOSI-2L-VISCERAL-PACLITAXEL